Anti-PSMA Purified

Anti-PSMA Purified
Regulatory status
RUO
Antigen
PSMA
Clone
GCP-04
Format
Purified
Reactivity
Pig, Mouse, Rat, Human
Application
Variant
0.1 mg
11-532-C100
In stock
209.00 USD

0.025 mg
11-532-C025
In stock
104.50 USD
Variant
0.1 mg
11-532-C100
In stock
209.00 USD

0.025 mg
11-532-C025
In stock
104.50 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody GCP-04 recognizes amino acids 100-104 of extracellular domain of denaturated glutamate carboxypeptidase II (PSMA, NAALADase, FOLH1), an approximately 95-110 kDa transmembrane glycoprotein.
Application
Application details
Western blotting: Recommended dilution: 1 μg/ml; positive control: LNCaP cell line. Sample preparation: Resuspend approx. 50 mil. cells in 1 ml cold lysis buffer (1% NP-40). Incubate 30 min on ice. Mix lysate with non-reducing/reducing Laemmli SDS-PAGE sample buffer. Both reducing and non-reducing conditions.
Reactivity
Pig, Mouse, Rat, Human
Immunogen
Recombinant fragment of human GCPII (amino acids 44-750) produced in S2 cells
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
GCP2, FOLH1, NAALADase I, PGGCP, FGGCP, FGCP,
Antigen description
Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-alpha-linked acidic dipeptidase I (NAALADase I), folate hydrolase (FOLH1), and prostate-specific membrane antigen (PSMA), is an approximately 95-110 kDa type II transmembrane glycoprotein expressed in various tissues. In nervous system GCPII cleaves abundant N-acetylaspartylglutamate, which is released from neurons in a calcium-dependent manner, to N-acetylaspartate and glutamate. As immoderate glutamate concentration is neurotoxic, GCPII contributes to pathological conditions regarding e.g. Alzheimer´s disease, Huntington´s disease, epilepsy, schizophrenia, stroke or neuropathic pain and appears to be an interesting therapeutic target. In jejunum GCPII hydrolyzes pteroylpoly-gamma-glutamate to folate and glutamate, enabling folate to be absorbed by gastrointestinal tract. GCPII, which is present in a number of tissues at low levels, is overexpressed in neovasculature of most solid tumours and is a target enzyme for diagnosis and treatment of prostate cancer. Normal human prostate express more mRNA coding for a cytosolic GCPII form truncated at the N-terminus (PSM´) than mRNA for membrane-bound GCPII, and this ratio is reversed upon malignant transformation.
Entrez Gene ID 2346
UniProt ID Q04609
11-532_IHC
Immunohistochemistry staining of GCPII in human medulla oblongata by GCP-04 monoclonal antibody. Mag. 40x; positive astrocytes in white matter.
11-532_IHC_2
Immunohistochemistry staining of GCPII in human prostate by GCP-04 monoclonal antibody. Mag. 400x; positive epithelium of the prostate glands.
11-532_IHC_3
Immunohistochemistry staining of GCPII in porcine kidney by GCP-04 monoclonal antibody. Highly positive proximal glomeruli.
11-532_WB
Western blotting analysis of human PSMA using mouse monoclonal antibody GCP-04 on lysates of LNCaP cell line and Jurkat cell line (PSMA non-expressing cell line; negative control) under reducing and non-reducing conditions. Nitrocellulose membrane was probed with 2 µg/ml of mouse anti-PSMA monoclonal antibody followed by IRDye800-conjugated anti-mouse secondary antibody.

General references:

Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ, Monti AL, Roos RP: Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9554-9.
PubMed
Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R: Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 2006, 25: 1375-1384
PubMed
Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ: Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl. Acad. Sci. USA 2005, 102: 5981-5986
PubMed

Product specific references:

Barinka C, Mlcochova P, Sacha P, Hilgert I, Majer P, Slusher BS, Horejsi V, Konvalinka J: Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. Eur. J. Biochem. 2004, 271: 2782-2790
PubMed
Barinka C, Sacha P, Sklenar J, Man P, Bezouska K, Slusher BS, Konvalinka J: Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci. 2004, 13: 1627-1635
PubMed
Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlcochova P, Hilgert I, Eckschlager T, Konvalinka J: Expression of glutamate carboxypeptidase II in human brain. Neuroscience 2007, 144: 1361-1372
PubMed
Rovenska M, Hlouchova K, Sacha P, Mlcochova P, Horak V, Zamecnik J, Barinka C, Konvalinka J: Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate 2008, 68: 171-182
PubMed
Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS, Konvalinka J: Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J. Neurochem. 2002, 80: 477-487
PubMed
Tykvart J, Navrátil V, Sedlák F, Corey E, Colombatti M, Fracasso G, Koukolík F, Bařinka C, Sácha P, Konvalinka J: Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA). Prostate. 2014 Dec;74(16):1674-90.
PubMed
Variant
0.1 mg
11-532-C100
In stock
209.00 USD

0.025 mg
11-532-C025
In stock
104.50 USD
Variant
0.1 mg
11-532-C100
In stock
209.00 USD

0.025 mg
11-532-C025
In stock
104.50 USD